Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 20, 2019 - Issue 7-8
Submit an article Journal homepage
6,247
Views
30
CrossRef citations to date
0
Altmetric
Clinical Trials

Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch

Carlayne JacksonUniversity of Texas Health Science Center at San Antonio, San Antonio, TX, USA, View further author information
,
Terry Heiman-PattersonTemple University Lewis Katz School of Medicine, Philadelphia, PA, USA, View further author information
,
Pamela KittrellUniversity of Texas Health Science Center at San Antonio, San Antonio, TX, USA, View further author information
,
Tatyana BaranovskyMitsubishi Tanabe Pharma America, Inc, Jersey City, NJ, USA, and View further author information
,
Glenn McAnanamaMitsubishi Tanabe Pharma America, Inc, Jersey City, NJ, USA, and View further author information
,
Laura BowerMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USAView further author information
,
Wendy AgneseMitsubishi Tanabe Pharma America, Inc, Jersey City, NJ, USA, and Correspondence[email protected]
View further author information
&
Mike MartinMitsubishi Tanabe Pharma America, Inc, Jersey City, NJ, USA, and View further author information
 show all
Pages 605-610 | Received 14 Feb 2019, Accepted 08 Jul 2019, Published online: 31 Jul 2019

References

  • Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy – a roundtable discussion. Am J Manag Care. 2018;24:S175–86.
  • Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
  • Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218–26.
  • Rilutek® (riluzole) [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2012.
  • Radicava® (edaravone injection) [package insert]. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation; 2018.
  • Beydoun SR, Rosenfeld J. Edaravone in amyotrophic lateral sclerosis—lessons from the clinical development program and the importance of a strategic clinical trial design. US Neurol. 2018;14:47–53.
  • Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, et al. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:242–9.
  • Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414–25.
  • Thakore NJ, Lapin BR, Kinzy TG, Pioro EP. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:483–94.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.